Juan Yan, Xiao-Min Li, Yan-Xin Zhang, Su-Mei Xu, Wan-Li Liu, Jie Guo, Xiao-Lei Hu, Ting Zou, Yu-Ying Xu, Ping-Sheng Xu
Clinical pharmacology in drug development 2021 JunThe aim of this study was to explore the bioequivalence of miglitol based on pharmacodynamic properties. The study was performed as a single-dose, randomized, open-label, 3-period, 3-way crossover trial over a 7-day washout period. Forty-eight subjects were randomly assigned into 3 groups: (1) miglitol test formulation/sucrose coadministration, (2) miglitol reference formulation/sucrose coadministration, and (3) sucrose administration alone. Serum glucose concentrations were measured by the hexokinase detection method. The peak serum glucose concentration (Cmax ) and the area under the serum glucose concentration-time curve through 4 hours (AUC0-4h ) were used as the main pharmacodynamic parameters to evaluate bioequivalence. The 90% confidence intervals for the geometric mean ratios of Cmax and AUC0-4h were 94.81%-101.07% and 98.82%-100.72%, respectively, which were all within the bioequivalence range of 80.00%-125.00%. The test and reference formulations of miglitol were pharmacodynamically bioequivalent during the trial. © 2020, The American College of Clinical Pharmacology.
Juan Yan, Xiao-Min Li, Yan-Xin Zhang, Su-Mei Xu, Wan-Li Liu, Jie Guo, Xiao-Lei Hu, Ting Zou, Yu-Ying Xu, Ping-Sheng Xu. Bioequivalence and Evaluation Parameters Based on the Pharmacodynamics of Miglitol in Healthy Volunteers. Clinical pharmacology in drug development. 2021 Jun;10(6):582-587
PMID: 33058553
View Full Text